86 related articles for article (PubMed ID: 15542191)
1. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects.
Schleiss MR; Bernstein DI; Passo M; Parker S; Meric C; Verdier F; Newkirk MM
Vaccine; 2004 Dec; 23(5):687-92. PubMed ID: 15542191
[TBL] [Abstract][Full Text] [Related]
2. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
3. Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1-70 kDa small nuclear ribonucleoprotein.
Curtis HA; Singh T; Newkirk MM
Eur J Immunol; 1999 Nov; 29(11):3643-53. PubMed ID: 10556820
[TBL] [Abstract][Full Text] [Related]
4. Lack of autoantibody production associated with cytomegalovirus infection.
Marshall BC; McPherson RA; Greidinger E; Hoffman R; Adler SP
Arthritis Res; 2002; 4(5):R6. PubMed ID: 12223109
[TBL] [Abstract][Full Text] [Related]
5. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
6. The genotype of mice influences the autoimmune response to spliceosome proteins induced by cytomegalovirus gB immunization.
Lipes J; Skamene E; Newkirk MM
Clin Exp Immunol; 2002 Jul; 129(1):19-26. PubMed ID: 12100018
[TBL] [Abstract][Full Text] [Related]
7. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
8. Human anti-nuclear ribonucleoprotein antigen autoimmune sera contain a novel subset of autoantibodies that stabilizes the molecular interaction of U1RNP-C protein with the Sm core proteins.
Satoh M; Richards HB; Hamilton KJ; Reeves WH
J Immunol; 1997 May; 158(10):5017-25. PubMed ID: 9144522
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection.
Newkirk MM; van Venrooij WJ; Marshall GS
Arthritis Res; 2001; 3(4):253-8. PubMed ID: 11438044
[TBL] [Abstract][Full Text] [Related]
10. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
[TBL] [Abstract][Full Text] [Related]
11. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
[TBL] [Abstract][Full Text] [Related]
12. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies that stabilize U1snRNP are a significant component of human autoantibodies to snRNP and delay proteolysis of sm antigens in vitro.
Satoh M; Akaogi J; Kuroda Y; Nacionales DC; Yoshida H; Yamasaki Y; Reeves WH
J Rheumatol; 2004 Dec; 31(12):2382-9. PubMed ID: 15570638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
15. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection.
Schleiss MR; Bourne N; Bernstein DI
J Infect Dis; 2003 Dec; 188(12):1868-74. PubMed ID: 14673766
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
17. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
18. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
[TBL] [Abstract][Full Text] [Related]
19. Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.
Palafox Sánchez CA; Satoh M; Chan EK; Carcamo WC; Muñoz Valle JF; Orozco Barocio G; Oregon Romero E; Navarro Hernández RE; Salazar Páramo M; Cabral Castañeda A; Vázquez Del Mercado M
Arthritis Res Ther; 2009; 11(1):R27. PubMed ID: 19232124
[TBL] [Abstract][Full Text] [Related]
20. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
